2020 Annual Meeting | C145 - Introduction to Primary Headache Disorders: Trigeminal Autonomic Cephalalgias and Other Primary Headaches, Including New Daily Persistent Headache, Cough, Exercise, and Thunderclap Headaches

�鶹��ýӳ��

2020 Annual Meeting | C145 - Introduction to Primary Headache Disorders: Trigeminal Autonomic Cephalalgias and Other Primary Headaches, Including New Daily Persistent Headache, Cough, Exercise, and Thunderclap Headaches

Date Tuesday 04/28/20

Time 01:00 PM - 03:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Christopher J. Boes, MD, F�鶹��ýӳ��

Topic(s) Headache

Learning Objectives Participants should be familiar with how to diagnose and treat various primary headache disorders; become familiar with the International Classification of Headache Disorders, 3rd edition; be able to define various subtypes of trigeminal autonomic cephalalgias; and identify specific treatment for these subtypes.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Program Level Introductory

Program Tracks Advanced Practice Provider

Recommended Audience Fellow, Resident, General Neurologist, Advanced Practice Provider

Teaching Styles Case-based, Didactic

Event Timeline
01:00 PM - 01:50 PM	Speaker	Trigeminal Autonomic Cephalalgias Christopher J. Boes, MD, F�鶹��ýӳ��
01:50 PM - 02:40 PM	Speaker	Other Primary Headache Disorders Juliana VanderPluym, MD
02:40 PM - 03:00 PM	Q&A	Questions and Answers

Faculty Disclosures
Christopher J. Boes, MD, F�鶹��ýӳ��	Dr. Boes has a non-compensated relationship as a Review Committee for Neurology member with ACGME that is relevant to �鶹��ýӳ�� interests or activities.
Juliana VanderPluym, MD	Dr. VanderPluym has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Neurology and Neuroscience Reports. The institution of Dr. VanderPluym has received research support from Amgen.